Advertisement

Topics

AstraZeneca's Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC

05:37 EDT 9 Oct 2017 | Pharmafile

AstraZeneca has announced that its immunotherapy Tagrisso (osimertinib) has been awarded Breakthrough Therapy Designation by the FDA for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

read more

Original Article: AstraZeneca's Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC

NEXT ARTICLE

More From BioPortfolio on "AstraZeneca's Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC"

Quick Search
Advertisement
 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...